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Abstract: Clostridium difficile infection (CDI) remains a substantial burden on healthcare 
systems and is likely to remain so given our reliance on antimicrobial therapies to treat 
bacterial infections, especially in an aging population in whom multiple co-morbidities are 
common. Antimicrobial agents are a key component in the aetiology of CDI, both in the 
establishment of the infection and also in its treatment. The purpose of this review is to 
summarise the role of antimicrobial agents in primary and recurrent CDI; assessing why 
certain antimicrobial classes may predispose to the induction of CDI according to a balance 
between antimicrobial activity against the gut microflora and C. difficile. Considering these 
aspects of CDI is important in both the prevention of the infection and in the development 
of new antimicrobial treatments. 
Keywords: Clostridium difficile; antimicrobial agents; resistance; reduced susceptibility; 
recurrence 
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1. Introduction 
Clostridium difficile infection (CDI) remains a substantial worldwide burden on healthcare systems, 
despite significant research and investment over the past four decades. CDI normally, but not 
exclusively, emerges following one or more course(s) of antimicrobial therapy for an unrelated 
condition, which perturbs microbial colonisation resistance within the host. Other risk factors that have 
been linked to the development of CDI include proton pump inhibitors and the use of anticancer agents. 
Antimicrobial therapy facilitates germination of C. difficile spores within the colon and production of 
toxin A and/or toxin B. C. difficile is the aetiological agent of pseudomembranous colitis (PMC) and is 
implicated in approximately 30% of cases of antibiotic-associated diarrhoea [1,2]. Most antimicrobial 
agents have been implicated in the induction of CDI, but clindamycin, third-generation cephalosporins, 
fluoroquinolones, and aminopenicillins are particularly noted for their propensity to induce CDI [3]. 
Despite improved clinical management strategies for CDI, healthcare costs for treating CDI remain high 
and were estimated at $1.1–3.2 billion in the USA [4,5]. CDI is a complex and multifactorial disease, 
involving the host immune response to C. difficile and its toxins, antimicrobial agents, their effect of the 
indigenous gut microflora and C. difficile, and the virulence of the infecting C. difficile strain (Figure 1). 
Antimicrobial agents are an intrinsic aspect of CDI; in both its induction and treatment. The widespread 
emergence of hypervirulent PCR ribotype (RT) 027 highlighted the potential importance of 
antimicrobial (fluoroquinolone) resistance in facilitating the epidemic spread of C. difficile clones [6]. 
This review will concentrate on antimicrobial susceptibility and resistance in C. difficile to the 
antimicrobial agents that induce and treat CDI, considering the prevalent ribotypes currently in 
circulation, mechanisms for reduced susceptibility and resistance, and pharmacokinetics of the 
antimicrobial agents. Furthermore, a prediction of antimicrobial agent washout will be estimated using 
mass-balance theory for a range of antimicrobials, to suggest how the timing of CDI (primary or 
recurrent) may be influenced by antimicrobial susceptibility. We will also explore how the susceptibility 
of important indigenous gut microflora groups may influence the risk of CDI. 
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Figure 1. Factors involved in the development of Clostridium difficile infection (CDI). Blue shaded boxes involve antimicrobial agents. PK, 
pharmacokinetics; PD, pharmacodynamics. Antimicrobial agents differ in their pharmacokinetics (PK) and therefore in the luminal 
concentration that is present (and bioactive) in the human colon. In order for CDI to develop, a patient must either acquire toxigenic C. difficile 
from an exogenous source or be colonised with an endogenous strain. The antimicrobial agent disrupts the indigenous microflora to an extent 
governed by its antimicrobial spectrum of activity and pharmacodynamic (PD) profile, and a steady state concentration of antimicrobial agent 
may be reached by the end of dosing. The antimicrobial agent (and C. difficile spores) may then be washed out of the colon to a sub-inhibitory 
concentration, the speed of which depends on the steady-state drug concentration in the colonic lumen and the colonic transit time of the patient. 
The observation and timing of CDI depends on host immunological factors, C. difficile-specific factors (antimicrobial susceptibility to the 
inciting agent and the inoculum density of spores), and the rate and extent of recovery in the indigenous gut microflora. C. difficile spores do 
not outgrow in the presence of supra-inhibitory concentrations of antimicrobial agents, but once concentrations are sub-inhibitory then CDI may 
develop assuming the nutritional environment is conducive for spore germination and outgrowth (this may indicate prolonged disruption of 
colonisation resistance) and also that there is no IgG antitoxin response in the patient. Antimicrobial therapy for CDI may then be initiated by 
clinicians, the initial success of which depends on the PK/PD profile of the therapeutic agent and the susceptibility of the C. difficile strain. 
Whether recurrent CDI is subsequently observed may then depend on the degree to which the CDI therapy has negatively impacted on the 
indigenous gut microflora, the concentration of C. difficile spores remaining in the colon of the patient, whether the antimicrobial agent may 
persist in the colon or potentially adhere to C. difficile spores, and whether an IgG antitoxin response is observed. 
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2. Ribosomally Active Antimicrobial Agents 
2.1. Clindamycin 
Clindamycin was the first antimicrobial agent linked to pseudomembranous colitis in the mid-1970s 
by Tedesco and colleagues in a prospective study of 200 patients [7]. The authors reported 21% incidence 
of diarrhoea and 10% incidence of pseudomembranous colitis (PMC) following exposure to 
clindamycin. The authors noted that risk of PMC was 3–4 times greater following oral rather than 
parenteral clindamycin. Subsequently (in the late 1970s), the aetiology of CDI was determined when 
both C. difficile and its cytotoxic activity were demonstrated in faeces from PMC patients [1,2]. 
Clindamycin use has declined since clinical observations that this agent was a potent antimicrobial for 
inducing CDI. Surveillance for clindamycin resistance in C. difficile has identified multiple possible 
resistance mechanisms. Indeed, before highly discriminatory molecular typing methods were available, 
resistance to clindamycin was one characteristic that suggested that C. difficile subtypes existed within 
the same endemic ribotype (RT) 001 strains [8]. Antimicrobial susceptibility in C. difficile to 
clindamycin varies substantially between RTs and also according to geographical location. Freeman and 
colleagues recently published the results of a prospective susceptibility testing trial (ClosER) which 
encompassed 22 European countries and 953 C. difficile isolates [9]. Wide variations in RT prevalence 
were observed between countries and clindamycin resistance (MIC ≥ 8 mg/L) was present in 49.6% of 
isolates in multiple (including prevalent) RTs; intermediate resistance (MIC 4 mg/L) and susceptibility 
(≤2 mg/L) were observed in 12.7% and 37.6% of isolates, respectively, with a MIC range of 0.125 to 
>64 mg/L [9]. Clindamycin-resistant C. difficile have also been observed in other studies in Europe, 
Asia, North America (including RTs 017, 018, 001), and the Middle East [10–23]. Indeed, outbreaks of 
CDI attributed to clindamycin resistant C. difficile have been reported for RT027 [24,25] and other 
genetic types [26], with clindamycin exposure documented as a specific risk factor in CDI outbreaks. 
RT is not necessarily a predictor of resistance, perhaps with the exception of fluoroquinolone resistance 
in epidemic clones of RT027, given that the majority of susceptibility studies demonstrate susceptible 
and resistant strains that share the same RT. 
A true understanding of MICs is governed by the susceptibility testing method employed. For 
simplicity, many testing studies use antimicrobial-gradient based methods such as the E-test 
(Biomerieux, Basingstoke, UK) or the M.I.C Evaluator strip (ThermoFisher Scientific, Waltham, MA, 
USA). A limitation of such methods is that definitive MICs often cannot be determined due to the  
pre-defined concentration range of the test strip; with the highest concentration for clindamycin being 
256 mg/L. Indeed, even for gold-standard methods such as agar incorporation MIC testing, antimicrobial 
concentrations are doubling dilutions, often with 256 mg/L as the highest concentration; drug solubility 
often limits the testing of higher concentrations for many agents. Clindamycin resistant C. difficile with 
MICs of 16 to >256 mg/L often possess the erythromycin ribosomal methylase B, encoded by erm(B), 
which is often located on mobile genetic elements [27,28] and for which there are multiple genetic 
organisations but no clear ribotype association [12]. Erm(B) confers clindamycin resistance via methylation 
of bacterial 23S rRNA, and consequent prevention of drug binding and antimicrobial activity. However, 
clindamycin-resistant erm(B) negative, and clindamycin-susceptible erm(B) positive C. difficile have 
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been reported [29]; thus, alternative mechanisms of resistance such as erm(B)-independent 23S rRNA 
methylation [12], efflux, or other unidentified mechanisms may be present in C. difficile. 
2.2. Erythromycin 
Erythromycin is a macrolide antimicrobial agent that inhibits protein synthesis in bacteria by binding 
the 50S ribosomal subunit and impairing the elongation cycle by preventing movement of the ribosome 
along the mRNA. Macrolides are not considered antimicrobial agents that have a strong association with 
CDI, although true risk data are difficult to obtain given that macrolides are often co-administered with 
other antibiotics; for example, with penicillins in the treatment of community-acquired pneumonia.  
C. difficile may be resistant to erythromycin via expression of erm(B) [12,30] or erm(FS) [31], 
methylation of 23S rRNA (erm(B)-independent) [12], mutation in 23S rDNA (C656T substitution in 
high-level erythromycin resistant and low-level clindamycin resistant, erm(B) negative C. difficile) [31], 
and a potential role for the cme efflux pump [32]. Similar to clindamycin, resistance to erythromycin 
varies within, and between RT and is characterised by MICs ≥ 8 mg/L (CLSI). In a recent study in Korea, 
of 1407 non-duplicated C. difficile isolates collected over 10 years, resistance (MICs 32 to >128) was 
seen in 3/4 of the most prevalent RT (001, 018, and 017), and in 80% of all C. difficile isolates [14]. 
Erythromycin resistance has also been demonstrated in hypervirulent RT027 [10,13,21] and 078 [33], 
and other prevalent RT such as 001 [10,21,34], and 017 [15]. There are 17 distinct genetic organisations 
of erm(B) (E1-E17) reported in C. difficile [12]. Erythromycin resistant C. difficile (erm(B) positive) 
appear to demonstrate reduced fitness in vitro in competition assays with susceptible strains, and in growth 
rate experiments [35]; whether such reduced fitness/virulence is present in vivo remains to be determined. 
2.3. Tetracyclines 
Tetracyclines inhibit protein synthesis by preventing the attachment of aminoacyl-tRNA to the 
ribosomal acceptor (A) site [36]. This family of antimicrobials is considered low-risk for induction of 
CDI, despite broad Gram-positive, Gram-negative, and anti-anaerobe spectra of activity. Tetracycline 
resistance in C. difficile was documented over 30 years ago and was demonstrated as transferable 
between C. difficile strains [37,38] and also other bacterial species [39]. Resistance to tetracyclines also 
varies widely between countries and with RT. In an ESGCD study in 2007, Barbut and colleagues 
observed no tetracycline resistant C. difficile in isolates from the UK and the Netherlands, 14.3% 
resistance in isolates from Poland, 21.4% resistance in isolates from Hungary, and 38.9% resistance in 
isolates from Greece; compared to 9.2% across the entire study [40]. In general, most susceptibility 
studies demonstrate resistance in <10% of isolates. The current CLSI breakpoint for resistance to 
tetracycline is ≥16 mg/L and obtaining definitive MICs is dependent on whether E-test or equivalent 
tests are used (maximum concentration 32 mg/L) or agar/broth MIC testing using doubling dilution 
concentrations. Tetracycline intermediate resistance (MIC 8 mg/L) has been demonstrated in RTs 014, 
017, 078 [33,40], resistance (MIC ≥ 16 mg/L) in RTs 012 and 048 [12], and higher-level resistance 
(MICs 32 to >256 mg/L) reported in 32 isolates of RT012 from Sweden [41] and in an additional 
comparative study of isolates from Shanghai and Sweden (MICs up to 64 mg/L) [15]. Resistance to 
tetracyclines may be mediated by efflux proteins, ribosomal protection mechanisms, or via enzymatic 
inactivation of the antimicrobial [36]. In C. difficile tetracycline resistance most often manifests as a 
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consequence of TetM production but may also be due to TetW [42,43]. Both TetM and TetW are 
cytoplasmic proteins with homology to elongation factors (EF-Tu and EF-G) that protect ribosomes from 
the action of tetracyclines by reducing their susceptibility to the antimicrobial [36]. The tet genes in  
C. difficile are carried on transposons related to Tn916 [44,45], i.e., Tn5397 [44,46], Tn6190 [47], 
Tn6235 [48]. Spigaglia and colleagues demonstrated the concurrent presence of tetM and tetW in three 
isolates of RT048 and one RT012 [12], yet it is unclear if expression of both tet elements elicits any 
further reduction in tetracycline MIC. Using a MIC breakpoint of ≥8 mg/L to examine human and pig 
isolates from the Netherlands and UK, 75/102 human strains and 15/56 porcine strains were resistant to 
tetracycline [49]. All tetracycline-resistant strains contained the Tn916-like transposon harbouring the 
tet(M) gene. DNA fingerprinting of strains demonstrated relatedness of porcine and human strains, 
which is notable given the widespread use of tetracyclines in animal husbandry [49]. 
2.4. Linezolid 
Linezolid is an oxazolidinone that is active against Gram-positive bacteria by inhibition of protein 
synthesis via targeting of bacterial 23S rRNA [50]. Linezolid is not currently used to treat CDI, but can 
inhibit exotoxin production in Gram positive cocci [51,52], has good activity against C. difficile 
including strains with reduced susceptibility to metronidazole [53–55], and inhibits cytotoxin production 
in complex in vitro models of CDI [53]. Although most C. difficile strains are inhibited by linezolid at 
concentrations far below the CLSI breakpoint for resistance (>4 mg/L), sporadic isolates with MICs of 
8–16 mg/L have been reported [53,56,57]. Baines and colleagues observed two C. difficile (RT023 and 
RT067) with MICs of 8 mg/L in a study of 118 C. difficile isolates; further testing of 27 RT023 isolates 
yielded no further resistant isolates [53]. Further analysis of the two linezolid resistant isolates by PCR 
and sequencing did not demonstrate mutations in 23S rRNA (unpublished data). A recent study of 891 
clinical isolates of toxigenic C. difficile yielded 9 isolates with elevated MICs (6–16 mg/L, RT001 (2/9), 
RT017 (6/9), and RT078 (1/9)) and PCR and sequencing identified the presence of cfr, which encodes a 
rRNA methyltransferase, in 7/9 C. difficile isolates on Tn6218, but not in the two RT001 isolates [56]. 
3. DNA and DNA/RNA Accessory Enzyme Inhibitors 
3.1. Fluoroquinolones 
Fluoroquinolones are synthetic derivatives of the naphthyridone molecule nalidixic acid, and were 
developed to increase inhibition of target molecules and broaden the antimicrobial spectrum [58]. 
Fluoroquinolones such as ciprofloxacin and moxifloxacin target DNA gyrase; specifically gyrA and gyrB 
in C. difficile, which encode the A and B subunits of the enzyme responsible for supercoiling bacterial 
DNA. Resistance to fluoroquinolones is well documented in C. difficile usually due to alterations in 
target structure via nucleotide substitutions (gyrA and/or gyrB) [6,12,59–62] within the quinolone-resistance 
determining region (QRDR) of DNA gyrase subunits; the role of efflux mediated resistance in C. difficile 
is unclear [12,63]. Considerable variability exists in C. difficile fluoroquinolone susceptibility within RT 
and between countries, with certain RT which are currently circulating being uniformly resistant to 
fluoroquinolones. The breakpoints for ciprofloxacin and moxifloxacin resistance are ≥32 mg/L 
(EUCAST ECOFF) and ≥8 mg/L respectively. A European prospective susceptibility testing 
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surveillance programme (ClosER) recently reported 2011–2012 results; 40% of 953 C. difficile were 
resistant to moxifloxacin, in multiple RTs, especially RT027 and RT356 [9]. Higher-level resistance to 
moxifloxacin is usually characterised by MICs ≥32 mg/L, with lower-level resistance eliciting MICs of 
8–16 mg/L; specific mutations within DNA gyrase subunits are associated with the magnitude of 
resistance. In a European surveillance study in 2008, Asp426-Val in gyrB was associated with high-level 
resistance to moxifloxacin [64], whereas in subsequent studies the same mutation was present in strains 
with only low-level resistance [14,65]; such observations suggest that other factors can influence 
resistance, possibly coupled with differences in gene expression. C. difficile strains may possess two 
concurrent substitutions in either gyrase gene, or a concurrent mutation in both gyrA and gyrB [65], 
however multiple concurrent mutations in both gyrase subunit genes have not been reported. Thr82-Ile 
is the most common gyrA substitution but Asp71-Glu, Pro116-Ala, Ala118-Ser, and Thr82-Ala also have 
been reported [12,64–68]. Mutations within gyrB may involve Asp426-Val, Asp426-Asn, Glu466-Val, 
Ser366-Ala, Leu444-Phe [12,14,59,64,65]. The acquisition of the Thr82-Ile gyrA substitution, in a 
clinical environment where fluoroquinolone use was substantial in the 1990–2000s [69], was a pivotal 
factor in the emergence of RT027 in the USA and Canada [6]. A recent whole genome sequencing and 
phylogenetic analysis of RT027 identified that the much highlighted changes in the PaLoc of C. difficile 
that were initially postulated as responsible for RT027 hypervirulence and transmission, were in fact 
present in pre- and post-epidemic RT027; yet the acquisition of fluoroquinolone resistance was the 
defining moment of the evolution and spread of the two lineages of this RT [6]. 
3.2. Rifamycins 
The rifamycins achieve selective toxicity in bacteria by targeting bacterial DNA-dependent RNA 
polymerase. Rifamycins (rifampicin and rifaximin) have been used to treat CDI due to very low MICs 
in (susceptible) C. difficile; rifaximin (but not rifampicin) is poorly absorbed after oral administration [70]. 
Rifampicin resistance in C. difficile has been reported in 0–17.5% of isolates [9,11,12,15,17,71,72]  
at a breakpoint of ≥16 mg/L, with resistant isolates seen in 17/22 countries in a recent pan-European 
study [9]. High prevalence of resistant isolates was observed in Italy (particularly RT018 and RT356), 
the Czech Republic, Denmark, and Hungary, with resistant isolates in RTs 017, 027, 176, and 001/072 
observed [9]. In a study of 80 clinical C. difficile isolates, O’Connor et al observed seven rpo(B) 
substitutions (14 C. difficile strains): Arg505-Lys, His502-Asn, -Tyr, -Arg, Ser488-Thr, Asp492-Asn, 
and Iso548-Met; therefore, several distinct substitutions, some at the same location, are associated with 
MICs >256 mg/L [71]. There is a bimodal distribution of rifampicin MICs in C. difficile, typically with 
results ≤0.016 mg/L and >256 mg/L [41]. Spigaglia et al. observed mutations in the β-subunit of RNA 
polymerase, encoded by rpo(B) (1 or 2 substitutions); specifically His502-Asn and Arg505-Lys (92% of 
resistant strains), Arg505-Lys alone (6% of resistant isolates), or His502-Asn alone (2% of isolates) [12]. 
Rifampicin resistance has been reported in multiple epidemic and non-epidemic RTs [12,22,72], 
including in multi-drug-resistant (MDR) strains. Mutations in rpo(B) between positions 488–548 may 
either disrupt the direct interaction between rifamycins and RpoB, or modify the rifamycin-binding 
pocket and therefore reduce the affinity of target for the antimicrobial [72,73]. Resistance has been 
described during treatment of CDI with rifamycins [74–76]. A RT056 isolate with a baseline rifaximin 
MIC of 0.002 mg/L became resistant (MIC ≥ 32 mg/L; His502-Tyr substitution) within 3 days of 
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rifaximin therapy [76]. A second substitution (Pro496-Ser) was also identified in a second RT056 isolate 
and both strains persisted for 49 days, following which the patient was treated with fidaxomicin; the 
isolate reverted to being rifaximin-susceptible, and the patient remained asymptomatically colonised for 
>30 days [76]. 
3.3. Fidaxomicin 
Fidaxomicin was the first new therapy to be licensed for the treatment of CDI in over 25 years; it is 
now recommended for use in initial or recurrent episodes of CDI [77]. Fidaxomicin is a macrocyclic 
narrow spectrum, bactericidal antimicrobial agent, which is poorly absorbed after oral administration, 
and targets bacterial RNA polymerase at a site distinct from rifamycins [78,79]. Fidaxomicin is very 
active against C. difficile, with MICs generally 0.02–0.25 mg/L [9]. Rare reports exist of fidaxomicin 
reduced susceptibility (MIC 2–4 mg/L) [80,81] or resistance (MIC 16 mg/L) [82]. However, even these 
higher MICs are approximately two orders of magnitude lower than the concentrations of fidaxomicin 
that are achieved in the gut lumen. Leeds et al. conducted laboratory studies exposing C. difficile to  
sub-inhibitory concentrations of fidaxomicin over 10 serial passages, with whole genome sequencing to 
characterise resistance mechanisms, and demonstrated a Glu-Arg nucleotide substitution at position 
1073 in rpo(B) or mutation within CD22120 (a marR homolog); resulting in a fidaxomicin MIC of  
4 mg/L [81]. 
3.4. Metronidazole 
Metronidazole achieves its antibacterial action by directly damaging bacterial DNA following 
reduction of its nitro group once inside a bacterium. Several reduction systems have been highlighted as 
important for the activation of metronidazole, but perhaps most important is the pyruvate-ferredoxin/ 
flavodoxin oxidoreductase (PFOR) system; pyruvate is decarboxylated to acetyly-CoA and concurrently 
electrons are transferred to the nitro group of metronidazole by ferredoxin or flavodoxin [83]. 
Metronidazole has been a primary treatment option for CDI for over 30 years. However, reduced efficacy 
was reported by Musher et al. [84] in a prospective observational study of 207 CDI patients, in which 
only 50% of patients were successfully treated, and 22% continued to experience symptomatic CDI 
despite ≥10 days of treatment. Furthermore, 28% of patients experienced symptomatic recurrence within 
90 days. Similar observations of reduced initial response to metronidazole and increased CDI recurrence 
have also been reported elsewhere [85]. 
Freeman and colleagues recently demonstrated that only 0.11% of 953 C. difficile were resistant to 
metronidazole (MIC ≥ 8 mg/L), with maximal MICs of 8 mg/L observed in a single RT106 isolate from 
the UK [9]. Interestingly, 20 isolates demonstrated reduced susceptibility to metronidazole (MIC 4 mg/L), 
of which 55% were RT027, isolated from the UK, Switzerland, Poland, Denmark, Germany, Denmark, 
the Czech Republic, and Hungary. Reduced susceptibility to metronidazole was reported in UK  
C. difficile RT001 (but not RT106 or RT027) in 2008 [86], but the clinical significance of this phenotype 
and the underlying mechanism is uncertain. RT027, RT106, and RT001/072 (and RT356) demonstrate 
elevated geometric mean metronidazole MICs compared with other RTs [9]. Metronidazole-resistant  
C. difficile have been reported in other studies [87–90] and resistance has been reported as heterogeneous, 
with slow-growing metronidazole resistant C. difficile within a population observed after extended 
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incubation periods using E-test [91]. It is important to note that the choice of MIC methodology is crucial 
to the detection of reduced susceptibility to metronidazole; E-tests in particular under-estimate the MIC 
of metronidazole [86,92]. 
Despite reports of reduced susceptibility/resistance to metronidazole, and modest faecal 
concentrations of metronidazole (approximately 9 mg/L), CDI treatment failure has not been linked to 
antimicrobial resistance in C. difficile [93]. Until recently, mechanisms of metronidazole resistance in 
C. difficile have remained elusive; resistant strains have not been described with nimA-J [94,95], which codes 
for the reduction of the nitro group of nitroimidazoles into a poorly active amine group [96]. Three recent 
studies have provided important information regarding metronidazole resistance in C. difficile [97–99]. 
Lynch et al. used comparative whole genome sequencing to analyse a stable metronidazole-resistant 
RT027 strain and a clone that reverted to metronidazole-susceptible after freeze-thawing [98]. In 
addition to point mutations within sporulation (spo0A) and germination (cspC) loci, the authors 
demonstrated mutations in the ferric uptake regulator (fur), a mutation in a putative nitroreductase gene 
(in both RT027 strains), and a mutation in the corporphyrinogrn III oxidase gene (hemN) (Table 1). In a 
subsequent proteomic analysis of the same RT027 strains, there was no evidence of involvement of 
deficiencies in the PFOR system [97]. However, the authors did observe increased production of the 
ferric uptake regulator protein in the metronidazole-resistant RT027; Fur is a central regulator of iron 
homeostasis in bacteria. Moura and colleagues analysed a metronidazole-resistant RT010 C. difficile 
strain using a quantitative proteomic approach on mid-log-phase cultures [99]. No aberrations in PFOR, 
hemN, fur, or nim were detected, but an absence of ferritin was observed in the metronidazole-resistant 
isolate when exposed to metronidazole; therefore deficient iron storage was postulated. Additionally, 
reduced ferredoxin reduction, and consequently metronidazole activation, was postulated due to the 
significant decreased expression of butyryl CoA dehydrogenase during metronidazole exposure [99].  
It should be noted that RT010 are generally non-toxigenic; also, transfer of metronidazole reduced 
susceptibility or resistance between C. difficile strains has not been demonstrated. 
Table 1. Mutations potentially contributing to reduced susceptibility and/or resistance to 
metronidazole (MTZ) in C. difficile. 
Gene/Protein 
implicated 
Potential Contribution to Metronidazole Resistance Ref. 
Ferric uptake regulator 
(fur) 
Point mutation could lead to altered binding of Fur to SOD therefore 
reduced oxidative stress in C. difficile in response to MTZ exposure. 
[97,98] 
Putative nitroreductase Frameshift mutation could affect activation of MTZ. [98] 
Coproporphyrinogen III 
Oxidase (hemN) 
Frameshift mutation could disrupt heme biosynthesis/metabolism, 
defective electron transport and reduced MTZ activation. 
[98] 
Ferritin 
Absence in MTZR strain under MTZ pressure  
therefore deficient iron storage 
[99] 
Butyryl CoA 
dehydrogenase (Bcd) 
Significant reduction under MTZ pressure, therefore possible reduced 
ferredoxin reduction and consequent reduction in MTZ activation. 
[99] 
Ferredoxin (2 proteins) 
Reduced expression in MTZR and revertant strains, possible reduction 
in MTZ activation. Another ferredoxin protein was increased in 
expression in MTZR and revertant strains. Unclear significance. 
[97] 
MTZR = metronidazole-resistant C. difficile. 
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4. Cell Wall Synthesis Inhibitors 
4.1. Vancomycin 
Much like metronidazole, vancomycin has been a first-line therapy for CDI for the past 3 decades; 
vancomycin concentrations typically exceed 1000 mg/L in faeces after oral administration. Vancomycin 
retains good activity against C. difficile, including against strains with reduced metronidazole 
susceptibility and also epidemic strains that tend to have higher geometric mean metronidazole MICs. 
Vancomycin binds to the C-terminal dipeptide, D-alanyl-D-alanine, of the NAM-pentapeptide of 
peptidoglycan (PG) precursors during PG synthesis, so preventing transpeptidation (cross-linking) 
reactions between adjacent peptide side chains of adjacent PG strains. Acquired resistance to 
vancomycin is well studied in Staphylococcus aureus and Enterococcus spp. and results from expression 
of one of 9 van gene clusters, which encode ligase enzymes that modify the terminal D-ala-D-ala of PG 
precursors [100]. The expression of vancomycin resistance is controlled by a 2-component regulatory 
system (VanSR). C. difficile has been shown to possess a vanG homolog [101,102] within its genome 
(vanGCd), which was recently assessed for its ability to confer vancomycin resistance. vanGCd is 
inducible by vancomycin, but does not promote vancomycin resistance in C. difficile. When vanGCd was 
cloned into a vancomycin-susceptible Escherichia coli strain, vancomycin resistance was conferred; 
therefore, it was postulated that there is some mechanism in C. difficile that prevents expression of 
vancomycin resistance [100]. Susceptibility to vancomycin was recently demonstrated in 97.8% of 953 
C. difficile isolates (MIC ≤ 2 mg/L). Reduced susceptibility to vancomycin has begun to emerge over 
the past 5 years (i.e., MICs ≥ 4 mg/L), but remains relatively sporadic. Recently, single isolates with 
intermediate-resistance (MIC 4 mg/L) have been seen from the Czech Republic, Ireland, Latvia, and 
Poland, and multiple isolates from Italy and Spain, resistant to vancomycin (MIC ≥ 8 mg/L), from 
multiple ribotypes (including RT027, RT126, RT356, and RT001/072) have been detected. No 
underlying mechanisms for such reduced susceptibility have been reported [9]. The authors of this study 
also commented that RT018 and RT356 (which are prevalent in Italy [9]) demonstrated notably higher 
vancomycin geometric mean MICs (2.00 mg/L and 2.28 mg/L, respectively) than other common 
ribotypes (0.62–0.95 mg/L). In a Swedish study, Noren and colleagues observed three RT002 isolates 
with vancomycin MICs 4-8 mg/L over a 2 year period in a patient who underwent long-term IV 
vancomycin therapy for S. aureus septicaemia [41]. 
4.2. Penicillins 
Broad spectrum β-lactam antimicrobial agents are well recognised for their propensity to induce CDI, 
e.g., aminopenicillins and cephalosporins. Conversely, some β-lactams when given as combination 
products with β-lactamase inhibitors, e.g., piperacillin-tazobactam, are not noted for their propensity to 
induce CDI, and indeed have been used in preference to cephalosporins to reduce CDI rates [103,104]. 
C. difficile susceptibility to β-lactams varies depending on the antimicrobial, with general susceptibility 
to β-lactam-β-lactamase inhibitor combinations, resistance to cephalosporins (although small numbers 
may be susceptible), and intermediate resistance or susceptibility to aminopenicillins. Noren et al. reported 
penicillin V and piperacillin MIC90 of 8 mg/L and 32 mg/L, respectively, in C. difficile isolates from Sweden 
over a 15 year period, with some isolates demonstrating high-level resistance (>256 mg/L) [41]. 
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5. Antimicrobial Susceptibility of the Indigenous Gut Microflora 
From early in vitro experiments exploring colonisation resistance [105], and its association with 
antimicrobial therapy [106], it was clear that the indigenous gut microflora played a pivotal role in gut 
homeostasis and the prevention of CDI. A new antimicrobial agent to treat CDI should be: (1) assessed 
for its propensity to disrupt the indigenous gut microflora such that CDI may emerge; (2) as narrow spectrum 
as possible, ideally C. difficile specific; and (3) have a favourable pharmacokinetic/pharmacodynamic 
profile. Researchers have assessed in vitro and in vivo the effects of antimicrobial agents commonly 
linked to CDI; measured endpoints include which populations of the indigenous gut microflora are 
adversely affected or are promoted, whether C. difficile can be isolated and what is the duration of toxin 
production following spore germination [53,62,105,107–124]. Identifying a small number of key 
bacterial groups responsible for colonisation resistance to CDI in amongst over 500 bacterial species in 
the human colon is obviously an extremely challenging feat, but one that has been attempted for over 
two decades [105,125–127]. Recent research into selective microbial restoration therapy [128] and feacal 
microflora transplantation (for review see [129]) has demonstrated positive outcomes in the treatment of 
CDI. However, to design optimal interventions that are targeted at CDI, and also to minimise the risk of 
selection of C. difficile, further research is needed to delineate which are the critical microbial factors in 
disease pathogenesis. Recurrent CDI occurs in approximately 20% of CDI cases following treatment 
with metronidazole or vancomycin, and this remains a key goal for improving therapeutic outcomes. 
5.1. Antimicrobial Agents Associated with CDI Induction 
Antimicrobial agents most commonly associated with CDI cause a shift from an anaerobe-dominated 
gut microflora in favour of facultative-anaerobes. Within the indigenous gut microflora, alterations in 
the community structure may occur over time in response to diet, stresses, antimicrobial agent exposure, 
and age, but the total concentrations of microbes remain relatively constant. The changes in gut 
microflora community structure associated with the administration of selected antimicrobial agents  
are presented in Table 2. From these in vitro and in vivo studies it is clear that antimicrobial agents that 
are potent inducers of CDI elicit widespread reductions in the anaerobic microflora, particularly 
Bacteroides spp. and Bifidobacterium spp., with a concurrent increase in certain populations of 
facultative anaerobes either during or after antimicrobial dosing, e.g., Enterococcus spp. and lactose-
fermenting Enterobacteriaceae. 
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Table 2. Changes in selected indigenous gut microflora populations following exposure to antimicrobial agents in vitro and in vivo. 
 
 Negatively Impacted Populations Positively Impacted Populations 
Refs 
Antimicrobial Agent Anaerobes Facultative Anaerobes Anaerobes Facultative Anaerobes 
Common inducers 
of CDI 
Clindamycin 
Bifidobacteria, Bacteroides, 
Eubacteria, Clostridia 
Lactobacilli No effect Enterobacteria, Enterococci 
[53,107,110–112, 
114,117,130] 
Ciprofloxacin 
Anaerobes overall, Bifidobacteria, 
Bacteroides spp., Clostridia 
E. coli (LFE), 
Lactobacilli, Enterococci 
No effect Enterococci (PD) [62,131] 
Moxifloxacin 
Bifidobacteria, Bacteroides fragilis 
group, Clostridia 
LFE, Enterococci No effect Enterococci (PD) [62] 
Levofloxacin * 
Bifidobacteria, Bacteroides fragilis 
group 
LFE, Enterococci, 
Lactobacilli 
No effect Facultative anaerobes overall [62] 
Co-amoxyclav 
Bifidobacteria, Bacteroides fragilis 
group, Clostridia 
No effect No effect Enterococci, LFE [132] 
Infrequent 
inducers of CDI 
Piperacillin tazobactam Bifidobacteria, Anaerobic cocci Lactobacilli, Enterococci No effect Enterococci, Lactobacilli, Clostridia (PD) [133] 
Piperacillin tazobactam 
Anaerobes overall, Bifidobacteria, 
Bacteroides fragilis group,  
Lactobacilli, LFE,  No Effect Enterococci, Lactobacilli, Clostridia (PD) [108] 
Mecillinam Bifidobacteria LFE No effect No effect [113] 
Erythromycin 
Bifidobacteria, Bacteroides, 
Clostridia 
E. coli, Streptococci, 
Lactobacilli, Enterococci 
Eubacteria No effect [134] 
PD, post-dosing; LFE, lactose-fermenting Enterobacteriaceae. Underlined bacterial groups were substantially reduced (≥3-log10 cfu/mL). * 1/2 experiments, second 
experiment demonstrated a reduced antimicrobial effect. 
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Culture-independent techniques have supplemented the data generated from culture-based studies.  
In a study of the intestinal microbiota of 25 CDI patients compared with those for 50 matched controls, 
Manges et al., used 16S rRNA microarray to show that the Bacteroidetes and Firmicutes phyla were 
associated with development of CDI [135]. Lactobacillus and Clostridium are two important members 
of the Firmicutes phylum. Additionally, Antharam and colleagues recently reported the results of a study 
of 39 CDI patients (vs. 36 non-CDI diarrhoea patients, and 40 controls), assessing the gut microflora 
composition, using culture-independent 454 16S rRNA Pyrosequencing [136]. The study reported 
marked decreases in microbial diversity and species richness, principally due to reduced Firmicutes 
phylum sequence reads. Furthermore, associations between the depletion of Ruminococcaceae, 
Lachnospiraceae, and butyrogenic bacteria in the gut microbiota and nosocomial diarrhoea, including 
CDI were noted [136].  
Such changes in gut microflora community structure, based on viable count data, correlate well with 
susceptibility studies and the concentrations of antimicrobial agent that are observed in faeces following 
dosing (Tables 2–4). Bifidobacterium spp. are in general susceptible to penicillins, macrolides, 
glycopeptides, and fluoroquinolones, but variations between species are observed [137]. Some 
Bifidobacterium spp. possess resistance determinants such as tetW [138], and erm(X) [139] to confer 
resistance to tetracyclines and erythromycin/clindamycin, respectively. Bacteroides spp. vary in 
susceptibility to co-amoxiclav, with MIC90s ranging from 4 to >128 mg/L [140] and also vary 
substantially in their susceptibilities to fluoroquinolones [140,141]. Stiefel et al. raised an interesting 
hypothesis that antimicrobial-resistant gut microflora may be protective in the gut when a patient is 
exposed to antimicrobial agents [142]. A cephalosporinase-producing Bacteroides thetaiotamicron was 
dosed orally into mice for 3 days, prior to administration of subcutaneous ceftriaxone and oral C. difficile 
spores, and showed that prior colonisation with the B. thetaiotamicron strain inactivated intra-intestinal 
cephalosporin and also prevented overgrowth by C. difficile [142]. If key protective bacterial species 
within the human colon were resistant to antimicrobial agents that were active in the induction of CDI, 
this may potentially stabilise host colonisation resistance, although possible transfer of resistance 
determinants to pathogenic bacterial species is an obvious concern. In a novel recent study assessing 
antimicrobial-induced gut microflora changes in mice and resultant susceptibility to CDI development, 
and correlating changes in gut microflora in hospitalized patients, Buffie and colleagues suggested that 
Clostridium scnidens may be a key protective species against CDI [143]. 
5.2. Antimicrobial Agents to Treat CDI: Metronidazole, Vancomycin, and Fidaxomicin 
Treatments for CDI also may adversely affect the indigenous gut microflora and therefore prolong 
the perturbation of the microflora; thus, putting an individual at risk of recurrent CDI either because 
persistent spores may germinate (CDI relapse) or if a new strain is acquired (CDI re-infection). The 
reduced efficacy of metronidazole may be to be due to a perturbed microflora [85,110,144–146] that is 
exacerbated by the CDI treatment drug, reduced or heterogeneous susceptibility to metronidazole in 
clinical C. difficile [86,91], and/or host factors including immunoresponsiveness to C. difficile  
and its toxins [147]. Mean metronidazole concentrations in faeces range from 0–26 mg/kg  
(approx. mg/L) [123,144,148–150] (Table 4) and levels decline as the colonic mucosal inflammation 
resolves [148]; therefore, only low, possibly sub-therapeutic, antibiotic concentrations may be present, 
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leading to inconsistent treatment outcomes. Assuming a supra-MIC of metronidazole, bactericidal 
activity may be demonstrated against key anaerobic gut microflora groups (Bifidobacterium spp. and 
Bacteroides spp.) and this, combined with rapid decline of antimicrobial concentration following 
cessation of dosing (i.e., washout), may allow C. difficile to compete for key nutrients [102] that are 
needed for growth and toxin production leading to recurrent infection.  
Table 3. Changes in selected indigenous gut microflora populations following exposure to 
CDI therapeutic antimicrobial agents in vitro and in vivo.  
Antimicrobial 
Agent 
Negatively Impacted Populations Positively Impacted Populations 
Refs 
Anaerobes 
Facultative 
Anaerobes 
Anaerobes 
Facultative 
Anaerobes 
Vancomycin 
Bifidobacteria, 
Bacteroides, Clostridia 
Lactobacilli, 
Enterococci 
No effect 
LFE PD. 
Lactobacilli (PD) 
[111,151] 
Metronidazole+ 
Bifidobacteria, 
Bacteroides, Clostridia 
No effect (one study 
E. coli) 
No effect LFE [110,152] 
Fidaxomicin Bifidobacteria Enterococci No effect LFE [146] 
PD, post-dosing; LFE, lactose-fermenting Enterobacteriaceae. Underlined bacterial groups were substantially 
reduced (≥3-log10 cfu/mL). + In studies where bioactive metronidazole was detected. 
Very high vancomycin levels occur in faeces following oral administration (1345–1406 mg/L) [123,150]. 
In healthy volunteers this results in marked reductions in Enterococcus spp. and Bacteroides spp., and 
increased numbers of facultatively-anaerobic Gram-negative bacilli (Klebsiella spp., Citrobacter spp., 
and Enterobacter spp.) [151]. Previous investigations also indicated the emergence of intrinsically-resistant 
Gram-positive bacteria during vancomycin therapy [151,153]. Instillation of vancomycin in a human  
in vitro gut model reported similar alterations in bacterial community structure [114]. Vancomycin-
susceptible Gram-positive bacterial groups (bifidobacteria and enterococci) were markedly reduced, 
while intrinsically-resistant Gram-positive groups such as lactobacilli and pediococci increased in 
number [114]. Interestingly, a marked reduction in Bacteroides spp. was demonstrated following 
vancomycin administration, in accordance with the observations of Edlund and colleagues [151]. Citron 
et al. demonstrated susceptibility to vancomycin in seventeen isolates of B. fragilis with MICs ranging 
from 16–128 mg/L; thus, very high concentrations of this anti-Gram-positive antibiotic are sufficient to 
adversely affect Gram-negative populations such as Bacteroides spp. [55]. 
Sears et al. analysed 175 faecal specimens from CDI patients who underwent a 200 mg twice-daily 
dose of fidaxomicin for 10 days and reported a mean (±SE) faecal concentration of 1396 mg/kg  
(±77.0) [154]. An active metabolite of fidaxomicin (OPT-1118) was also detected in faecal specimens 
and is also active against C. difficile. With fidaxomicin achieving such high faecal concentrations there 
is the potential that it may disrupt the indigenous gut microflora, even species with raised MICs. 
Susceptibility testing data indicated that fidaxomicin has good activity against C. difficile,  
C. perfringens, C. innocuum (MICs < 0.125 mg/L), but also has activity against other Gram-positive 
bacteria such as Bacillus spp. (MIC 1 mg/L), Enterococcus spp. (MIC 4 mg/L), Lactobacillus casei (but 
not L. acidophilus) (MIC 1 mg/L), Micrococcus luteus (MICs ≤ 0.06 mg/L), Bifidobacterium spp.  
(MICs ≤ 0.25 mg/L), and anaerobic cocci (MICs ≤1 mg/L). Additionally, some anti-Gram-negative 
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activity was demonstrated against Moraxella cattharalis (MIC ≤ 2 mg/L) and Acinetobacter calccoaceticus  
(MIC 1 mg/L) [155,156]. Conventional susceptibility data does not tell us the actual effect of fidaxomicin 
on the gut microflora, where indigenous microorganisms are exposed to very high antibiotic concentrations 
of fidaxomicin, and what the potential effect on colonisation resistance is. 
Gut model and in vivo studies offer insights into the effects of CDI therapeutics on gut  
microflora [146,157]. In an in vitro gut model fidaxomicin is effective in treating simulated primary and 
recurrent CDI [146]; inhibition of Bifidobacterium spp. was seen in three of four gut model experiments 
and the microflora became dominated by lactose-fermenting Enterobacteriaceae. Despite these 
microflora changes, fidaxomicin instillation was not associated with recurrent CDI, possibly due to 
persistence of supra-MICs of fidaxomicin for 2–3 weeks after dosing cessation, so preventing C. difficile 
spore germination. No inhibitory activity against Bacteroides spp. was observed, as would be predicted 
from in vitro susceptibility testing [155,156]. Another way of delineating the potential for recurrent CDI 
associated with a therapeutic is to measure the antibiotic-mediated inhibition of C. difficile spore 
outgrowth [158]. 
6. Role of C. difficile Antimicrobial Susceptibility in CDI Induction and Treatment 
Trying to assess the importance of the susceptibility of C. difficile to antimicrobial agents is not as 
simple as it might first appear, since CDI may result from the administration of antimicrobial agents to 
which the infecting strain is either susceptible or resistant. It is the timing of CDI that may differ; earlier 
infection may occur if a C. difficile strain is resistant to an antimicrobial agent. In vitro experiments with 
a human chemostat model of the colon clearly demonstrate C. difficile spore germination, outgrowth, and 
toxin production occur once bioactive antimicrobial concentrations decline to sub-MIC levels [110,111]. 
There are of course many other factors than simply antimicrobial concentrations that interplay to 
facilitate CDI (Figure 1). 
By using a mass-balance analysis of faecal concentrations of antimicrobial agents, it is possible to 
predict how quickly antimicrobials will be washed out of the gut and therefore analyse the potential 
importance of elevated MICs (Table 4). It should be noted that these estimations assume no binding of 
or inactivation of the antimicrobial. Human colonic transit times vary from 20–120 h, and are often 
slower in the elderly [159,160]. Selecting an appropriate gut transit time and corresponding dilution rate 
(1/transit time, h−1) is complicated by the variability between subjects. For the present predictions, the 
gut transit time was based upon the rate of washout of vancomycin observed in the study of Abujamel 
et al. (vancomycin concentrations kindly supplied by Dr Curtis Donskey) [123]. By selecting a gut transit 
time of 35 h (Dilution rate = 0.029 h−1), washout to <1 mg/L vancomycin would be achieved by day 11 
after dosing ceased, which reflects the data published in [123] (Figure 2). Using this same method it can 
be calculated that for a C. difficile strain with a vancomycin MIC of 4 mg/L, spores would be able 
potentially to germinate and outgrow 2 days before a strain that had an MIC of 1 mg/L; i.e., day 9 vs. 11 
post cessation of vancomycin dosing, assuming a faecal concentration of 1350 mg/L at the end of dosing. 
This may therefore provide a competitive advantage for strains with reduced vancomycin susceptibility; 
strains with an MIC of 8 mg/L could potentially germinate/outgrow a day earlier still. 
Importantly, germination, outgrowth, and proliferation of C. difficile will also be part-determined by 
the extent of persisting colonisation resistance disruption that is either due to the original CDI inducing 
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antibiotic(s) and/or the therapeutic agent. If we consider a “fidaxomicin-resistant” C. difficile strain with 
an MIC of 16 mg/L, spores could germinate/outgrow 7 days after cessation of fidaxomicin dosing, 
whereas susceptible strains (MIC 0.06 mg/L) would be inhibited from outgrowing until 15 days after 
cessation of fidaxomicin dosing if we assume concentrations in faeces were 1400 mg/L and no additional 
persistence due to spore binding or sequestration within gut biofilms. For metronidazole reduced 
susceptibility strains (MIC 4–8 mg/L) there is the possibility that luminal metronidazole concentrations 
during CDI therapy would be sub-MIC and therefore not inhibit C. difficile. If we assume that 15 mg/L 
of metronidazole was present at the end of a dosing regimen, then spores of C. difficile with MICs of  
4 or 8 mg/L would be able to germinate/outgrow after 1 to 2 days following cessation of metronidazole 
dosing, compared to 5 days for a strain with an MIC of 0.5 mg/L. Abujamel et al. commented that there 
was a 3 week vulnerable period for re-establishment of C. difficile colonization after CDI treatment  
with vancomycin or metronidazole [123]. This observation is consistent with predicted concentrations 
of vancomycin and metronidazole falling below the MIC for C. difficile that are susceptible to 
vancomycin/metronidazole. 
These same principles can be applied to the other antimicrobial agents which commonly induce CDI 
(Table 4), with an obvious selective advantage for C. difficile with reduced drug susceptibility or 
resistance, when proliferation may occur before gut microflora colonisation resistance has normalised. 
 
Figure 2. Predicted washout of vancomycin (mg/L) using a mass-balance calculation 
assuming a gut transit time of 35 hours (dilution rate = 0.029 h−1). Vancomycin concentrations 
(mean ± SE) are from Abujamel et al. [123,161] and mg/kg were assumed to equal mg/L. 
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Table 4. Predicted washout of antimicrobial agents from the human colon using a mass-balance calculation assuming a gut transit time of  
35 h (dilution rate = 0.029 h−1) and representative steady-state concentrations observed during antimicrobial dosing based on published data. 
Antimicrobial 
Agent 
Representative Steady-
State Concentration 
(mg/L) 
Washout Time (days) to Achieve Residual Antimicrobial 
Concentration Faecal/bile (B) 
Concentrations in vivo 
(mg/kg) 
Refs 
32 mg/L 16 mg/L 8 mg/L 4 mg/L 2 mg/L 1 mg/L 
Metronidazole 15 NR NR 1 2 3 4 0, 9.3, 26 [123,144,148,149,162] 
Vancomycin 
Fidaxomicin 
1350  
1400 
6 7 8 9 10 11 
1345,1406  
1396 
[123,150] 
[154] 
Clindamycin 
Ciprofloxacin 
150 3 4 5 6 7 8 
33.9(B), 97, 147.4, 203.8 136.8, 
168.5, 891 
[130,163–165] 
[131,165,166] 
Erythromycin 
Moxifloxacin 
500 5 6 7 8 9 10 
330, 978  
573.3 
[134,164] 
[167] 
Rifaximin 8000 9 10 11 12 13 14 7961 [168] 
NR = Not a relevant concentration for this antimicrobial agent. 
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7. Conclusions 
So what does all of this mean for existing and new CDI treatments? The preferred characteristics of 
the ideal CDI therapeutic are easy to state: Potent bactericidal activity against all C. difficile ribotypes, 
low potential for mutational resistance, narrow spectrum activity that results in minimal gut microflora 
disruption, a good pharmacokinetic profile that yields high enough luminal concentrations sufficient to 
inhibit/kill C. difficile that leads to washout of residual toxins and spores (although biofilm retention of 
toxins/spores may complicate this aim), and finally no recurrence of CDI after excretion of antibiotic. 
The efficacy of the antimicrobial against C. difficile and the indigenous gut microflora, and likelihood 
of recurrence can be assessed using in vitro models and to a lesser extent in animal models of CDI, but 
human trials are where the most pivotal data are generated. 
One aspect not evaluated extensively in this review is the effect of the antimicrobial agent on the 
physiology of C. difficile and the normal gut microflora at the levels of gene transcription and translation. 
Antimicrobial agents have been studied for their effects against C. difficile at sub-MIC in several studies 
at the transcriptional and also the whole organism levels [169–172] and been shown to affect the toxin 
production and expression of colonisation structures of C. difficile. These studies demonstrate interesting 
observations but based on the faecal concentrations presented in Table 4 should be interpreted with 
caution as they rely on vegetative C. difficile being exposed to sub-MIC which may not be the case in 
all CDI patients. Novel antimicrobial agents, both CDI therapeutics and agents for other infections, 
would ideally not stimulate C. difficile to express virulence determinants or elevate their levels of 
expression. However, such considerations are not necessarily criteria for discounting the development 
of an agent and these types of studies are not often performed in drug development programmes. In terms 
of preventing CDI, it is imperative that resistance development in C. difficile is limited as this provides 
C. difficile with a competitive advantage as it may facilitate CDI earlier in the course of a therapeutic 
antimicrobial. Reduced susceptibility to metronidazole may potentially result in therapeutic failure due 
to low bioactive drug concentrations in the colon and could predispose to greater likelihood of recurrent 
CDI, although clinical data supporting this hypothesis are lacking. Conversely, reduced susceptibility to 
fidaxomicin and vancomycin is unlikely to affect primary treatment efficacy for CDI due to very high 
luminal concentrations in the gut. Antimicrobial agents are integral in the aetiology of CDI and although 
resistance is not a prerequisite for CDI to occur, there is now substantial evidence that mutation to a 
resistant phenotype may confer a significant selective advantage within the gut ecosystem. Limiting the 
spread of antimicrobial resistance in C. difficile should be a primary goal for clinicians and scientists, 
and prospective monitoring of resistance phenotypes and genotypes are essential in achieving this. 
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